Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.6250
+0.0450 (7.76%)
Feb 20, 2026, 4:00 PM EST - Market closed
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 105 employees as of December 31, 2024. The number of employees decreased by 25 or -19.23% compared to the previous year.
Employees
105
Change (1Y)
-25
Growth (1Y)
-19.23%
Revenue / Employee
n/a
Profits / Employee
-$722,648
Market Cap
25.52M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 105 | -25 | -19.23% |
| Dec 31, 2023 | 130 | 23 | 21.50% |
| Dec 31, 2022 | 107 | 35 | 48.61% |
| Dec 31, 2021 | 72 | 24 | 50.00% |
| Mar 31, 2021 | 49 | - | - |
| Dec 31, 2020 | 48 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| IGC Pharma | 70 |
| Boundless Bio | 64 |
| Vistagen Therapeutics | 59 |
| Senti Biosciences | 34 |
| Daré Bioscience | 23 |
| Skye Bioscience | 16 |
| Rallybio | 15 |
BRNS News
- 4 months ago - ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PRNewsWire
- 5 months ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 5 months ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire
- 9 months ago - Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 - Accesswire
- 1 year ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 1 year ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 1 year ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 1 year ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire